EPH Stats & Data

Ethylphenidate emerged on the recreational drug market around 2010-2011 and gained increasing popularity over the subsequent years. It became primarily distributed as a research chemical through online vendors, exploiting its grey-area legal status in various jurisdictions during this period. The substance was also stocked by head shops in major cities across the United Kingdom and elsewhere, where it was sometimes sold both as a standalone product and as a component of blended preparations. One notable example was certain formulations marketed as "GoGaine," which combined ethylphenidate with other substances including MPA, lidocaine, and mannitol. An interesting aspect of ethylphenidate's pharmacological history relates to its endogenous formation within the human body. Small quantities of ethylphenidate can be produced through hepatic transesterification when ethanol and methylphenidate are co-ingested. This metabolic pathway parallels the formation of cocaethylene when cocaine and alcohol are consumed together. However, only a small percentage of consumed methylphenidate undergoes this conversion, meaning pharmacologically significant concentrations with measurable physiological effects would not typically be produced through this mechanism under normal circumstances. The phenomenon is most likely to occur in scenarios involving large quantities of both substances, such as in cases of non-medical use or overdose.

Forked from Subjective Effect Documentation by Josie Kins, September 2015. Via dose.wiki (CC0).

The toxicity and long-term health effects of recreational ethylphenidate use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because ethylphenidate has a very limited history of human usage. Anecdotal evidence from people who have tried ethylphenidate within the community suggests that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). It is worth noting that ethylphenidate crystals are particularly abrasive and somewhat caustic to mucous membranes.

Effects aggregated from 32 experience reports (32 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

Not drawn, too few reports (a dose tier needs 20): Insufflated Threshold (n=11). Why 20?

Dose distribution from experience reports, one dose per report (the first listed). Values above Q3 + 3×IQR are left out as outliers.

From 113 individual dose entries. Values above Q3 + 3×IQR are left out as outliers.

Most co-occurring substances, as a share of all 51 reports filed under EPH; whiskers are 95% intervals

Most common forms and preparations, as a share of the 46 reports that give one; whiskers are 95% intervals

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Values above Q3 + 3×IQR are left out as outliers.

Redosing behavior across 49 reports